Skip to main content
  • Saved

Commented on 's Post

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial - PubMed

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33848462/

1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: matasarm@mskcc.org. 2 Centro de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil. 3 Ankara University School of Medicine, Ankara, Turkey. 4 Fudan University Shanghai Cancer Center, Shanghai, China. 5 The First Hospital of Jilin University, Changchun, China.

  • 5 days 22 hours
    In a good prognostic subset of relapsed FL, pi3k copa added a pfs gain to rituxan therapy with manageable aes